作者
Luca Rinaldi, Alessandro Perrella, Maria Guarino, Massimo De Luca, Guido Piai, Nicola Coppola, Pia Clara Pafundi, Fortunato Ciardiello, Morena Fasano, Erika Martinelli, Giovanna Valente, Riccardo Nevola, Caterina Monari, Lucia Miglioresi, Barbara Guerrera, Massimiliano Berretta, Ferdinando Carlo Sasso, Filomena Morisco, Antonio Izzi, Luigi Elio Adinolfi
发表日期
2019/12
期刊
Journal of Translational Medicine
卷号
17
页码范围
1-10
出版商
BioMed Central
简介
Background
An unexpected increased HCC recurrence and occurrence rate among HCV patients treated with direct acting antivirals combination has been reported. Aim of the study was the evaluation of early HCC occurrence rate and its risk factors in a HCV infected population, treated with direct-acting-antivirals.
Methods
According to the Italian ministerial guidelines for direct-acting-antivirals treatment, 1022 consecutive HCV patients treated with direct-acting-antivirals were enrolled. Patients either with active HCC at imaging or history of previous treated HCC, HBV or HIV co-infection, or liver transplant recipients were excluded. The SVR, defined as the persistent absence of detectable serum HCV-RNA 12 weeks after the end of treatment (SVR12), was assessed for all enrolled patients. Abdominal ultrasound was performed before starting antiviral …
学术搜索中的文章
L Rinaldi, A Perrella, M Guarino, M De Luca, G Piai… - Journal of Translational Medicine, 2019